238 related articles for article (PubMed ID: 32993661)
1. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine.
Sun D; Mi K; Hao H; Xie S; Chen D; Huang L
BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus Pleuropneumoniae in a piglet tissue cage infection model.
Zhang L; Wu X; Huang Z; Zhang N; Wu Y; Cai Q; Shen X; Ding H
Vet Microbiol; 2018 Jun; 219():100-106. PubMed ID: 29778180
[TBL] [Abstract][Full Text] [Related]
3. Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling.
Dorey L; Pelligand L; Lees P
BMC Vet Res; 2017 Jul; 13(1):209. PubMed ID: 28666426
[TBL] [Abstract][Full Text] [Related]
4. Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.
Wang H; Liao C; Ding K; Zhang L; Wang L
BMC Vet Res; 2024 Jun; 20(1):241. PubMed ID: 38831324
[TBL] [Abstract][Full Text] [Related]
5. Optimizing tylosin dosage for co-infection of
Lee EB; Abbas MA; Park J; Tassew DD; Park SC
Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/pharmacodynamic evaluation of marbofloxacin in the treatment of Haemophilus parasuis and Actinobacillus pleuropneumoniae infections in nursery and fattener pigs using Monte Carlo simulations.
Vilalta C; Giboin H; Schneider M; El Garch F; Fraile L
J Vet Pharmacol Ther; 2014 Dec; 37(6):542-9. PubMed ID: 24903473
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets.
Zhou YF; Bu MX; Liu P; Sun J; Liu YH; Liao XP
BMC Vet Res; 2020 Mar; 16(1):81. PubMed ID: 32138735
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
J Vet Pharmacol Ther; 2017 Oct; 40(5):505-516. PubMed ID: 28090673
[TBL] [Abstract][Full Text] [Related]
10. PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs.
Li XD; Chi SQ; Wu LY; Liu C; Sun T; Hong J; Chen X; Chen XG; Wang GS; Yu DJ
BMC Vet Res; 2019 Aug; 15(1):272. PubMed ID: 31370843
[TBL] [Abstract][Full Text] [Related]
11. Exposure time-dependent bactericidal activities of amoxicillin against Actinobacillus pleuropneumoniae; an in vitro and In vivo pharmacodynamic model.
Tanigawa M; Sawada T
J Vet Med B Infect Dis Vet Public Health; 2003 Nov; 50(9):436-42. PubMed ID: 14633197
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Korea using new standardized procedures.
Kim B; Min K; Choi C; Cho WS; Cheon DS; Kwon D; Kim J; Chae C
J Vet Med Sci; 2001 Mar; 63(3):341-2. PubMed ID: 11307940
[TBL] [Abstract][Full Text] [Related]
13. Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine
Luo W; Wang D; Qin H; Chen D; Pan Y; Qu W; Huang L; Xie S
J Vet Sci; 2021 Nov; 22(6):e41. PubMed ID: 34854264
[TBL] [Abstract][Full Text] [Related]
14. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
15. Serotypes, antimicrobial susceptibility, and minimal inhibitory concentrations of Actionbacillus pleuropneumoniae isolated from slaughter pigs in Taiwan (2002-2007).
Yang CY; Lin CN; Lin CF; Chang TC; Chiou MT
J Vet Med Sci; 2011 Feb; 73(2):205-8. PubMed ID: 20948169
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance of Actinobacillus pleuropneumoniae isolated from swine.
Vanni M; Merenda M; Barigazzi G; Garbarino C; Luppi A; Tognetti R; Intorre L
Vet Microbiol; 2012 Apr; 156(1-2):172-7. PubMed ID: 22104584
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility testing of Actinobacillus pleuropneumoniae in Denmark. Evaluation of three different media of MIC-determinations and tablet diffusion tests.
Aarestrup FM; Jensen NE
Vet Microbiol; 1999 Feb; 64(4):299-305. PubMed ID: 10063535
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Actinobacillus pleuropneumoniae, Escherichia coli, and Salmonella choleraesuis recovered from Taiwanese swine.
Chang CF; Chang LC; Chang YF; Chen M; Chiang TS
J Vet Diagn Invest; 2002 Mar; 14(2):153-7. PubMed ID: 11939337
[TBL] [Abstract][Full Text] [Related]
19. Integration of pharmacokinetic-pharmacodynamic for dose optimization of doxycycline against Haemophilus parasuis in pigs.
Zhang L; Li Y; Wang Y; Sajid A; Ahmed S; Li X
J Vet Pharmacol Ther; 2018 Oct; 41(5):706-718. PubMed ID: 29696661
[TBL] [Abstract][Full Text] [Related]
20. Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens.
Dorey L; Lees P
BMC Vet Res; 2017 Jun; 13(1):192. PubMed ID: 28645327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
